The European Affiliate of the International Alliance for Biological Standardization (IABS-EU) and the Association of European Manufacturers of Autogenous Vaccines & Sera (EMAV) would be pleased to welcome you to the upcoming Autogenous Vaccines Hybrid Meeting. For those who are not registered yet, the meeting will take place in the format of a hybrid meeting: attendance in person or via video will be possible.
Most of the speakers are planning to attend onsite, offering the opportunity for productive discussions with the speakers and attendees. Only in the case of new emergency restrictions issued by the competent authorities would we would shift the meeting into a fully virtual one.
The meeting is intended to stimulate conversations between manufacturers, competent authorities, users, and other interested parties to develop a draft proposal on how to form a “common market approach” that will improve overall animal disease control in the community, especially for diseases that suffer from a lack of conventionally-authorised products. The proposal should support the efforts of the French and Czech EU-Presidencies in 2022.
Key items will include the evolution of GMP/GMP-like requirements, mutual recognition of inspections, critical quality and facility expectations, import and export considerations, relevance and impact on diagnostics, and the impact of vaccinated animals on epidemiological surveillance.
EMAV has issued a proposal for GMP conditions for Autogenous Vaccines. It is available under EMAV website.
For more information please have a look at IABS congress website.